Welcome to our dedicated page for Asahi Kaisei Adr news (Ticker: AHKSY), a resource for investors and traders seeking the latest updates and insights on Asahi Kaisei Adr stock.
News for ASAHI KAISEI CRP UNSP/ADR (AHKSY) reflects the breadth of Asahi Kasei Corporation’s activities across its Healthcare, Homes, and Material sectors. Company announcements highlight how this diversified manufacturer is reshaping its portfolio, advancing medical technologies, and developing new materials and electronic components.
In Healthcare, recent news features ZOLL Medical, an Asahi Kasei company, and its LifeVest wearable cardioverter defibrillator. Updates describe launches of next-generation LifeVest systems and garments, along with references to clinical evidence and AI-enhanced algorithms designed to reduce false alarms. Asahi Kasei Pharma also appears in news items, including the planned relocation of its global R&D hub to Shonan Health Innovation Park to strengthen drug discovery and open innovation.
Within the Material sector, news coverage includes Asahi Kasei Microdevices (AKM) and its sensing technologies, such as millimeter-wave radar solutions for real-time swallowing detection, gesture recognition based on electromyography, and AgeTech and PetTech applications like fall detection, smart diapers, cage monitoring systems, and smart pet collars. Other articles highlight advanced materials, including PIMEL™ photosensitive dielectric recognized by a TSMC Excellent Performance Award, and battery-related innovations such as high ionic conductive electrolyte technology licensed to EAS Batteries.
Investors and followers of AHKSY can use this news stream to track Asahi Kasei’s portfolio transformation under its "Trailblaze Together" plan, including structural reforms like the divestiture of the Daramic lead battery separator business, the planned phase-out of hexamethylene diamine production, and the integration of Asahi Kasei Advance with Teijin Frontier. Bookmark this page to monitor ongoing developments in pharmaceuticals, critical care, electronics, advanced materials, and sustainability-related initiatives that Asahi Kasei highlights in its public communications.
Asahi Kasei will unveil its AKXY2 concept car at K 2022 in Düsseldorf, Germany, from October 19-26. This model showcases the company's advanced technology and sustainable materials, including innovative particle foams and bio-based fillers aimed at electric vehicles. Key materials on display include polycarbonates produced using CO2 as a raw material and premium microfiber Dinamica®. The AKXY2 also features cellulose-based materials and next-gen engineering plastics. Asahi Kasei emphasizes its commitment to sustainability and innovation across its diverse product portfolio.
Asahi Kasei Bioprocess America will showcase its MOTIV™ Buffer Management Technology at ACHEMA 2022 in Frankfurt, scheduled from August 22-26, 2022. This innovative system blends buffers from concentrates in small, single-use bags, significantly enhancing efficiency and precision in pharmaceutical production. It has received multiple accolades, including ‘Best in Show’ at Interphex 2017 and ‘Technology of the Decade’ from Bioprocess International in 2012. The system supports rapid and sustainable pharmaceutical manufacturing, allowing medicines to reach patients globally faster.
Summary not available.
Asahi Kasei has developed a new system for calculating the carbon footprint (CFP) of its synthetic rubber and elastomers products, which will start providing data to customers from June 2022. The system utilizes the DEEP group-wide management infrastructure for enhanced CFP visualization and reduction strategies. Asahi Kasei aims for carbon neutrality by 2050, incorporating sustainable practices like using butadiene derived from plastic waste. This system is crucial as regulations on carbon footprints increase, and it tailors data to meet customer requirements.
Asahi Kasei has developed a new platform in collaboration with NTT DATA to monitor greenhouse gas (GHG) emissions and calculate carbon footprints for its performance plastics used in various industries. This initiative, part of its sustainability efforts, began in April 2022, with customer data sharing starting in May 2022. The platform aims to provide detailed insights into GHG emissions across the supply chain, enhancing accountability and supporting decarbonization. Asahi Kasei remains committed to achieving carbon neutrality by 2050.
Asahi Kasei Medical announced on April 14, 2022, the acquisition of Bionova Scientific, LLC, specializing in biopharmaceutical contract development and manufacturing. This strategic move enhances Asahi Kasei's bioprocess business, allowing it to offer advanced manufacturing capabilities for next-generation antibody drugs. Bionova's GMP-compliant facility and expertise in complex biopharmaceuticals are set to meet increasing market demand. The acquisition is pending necessary regulatory approvals.
Summary not available.
Asahi Kasei will showcase its AKXY Pod automotive interior prototype at the SAE World Congress Experience in Detroit from April 5-7, 2022. The presentation includes advancements in keeping vehicle cabins safe from pathogens using Crystal IS's Klaran UVC LEDs. The Healthy Car Portfolio emphasizes safety through technologies like touch-free alcohol sensors and innovative textiles. The event will highlight solutions for enhancing comfort and cleanliness in vehicles while addressing post-COVID-19 market needs, emphasizing the importance of healthy automotive innovations.
Asahi Kasei has announced a strategic partnership with Genomatica to develop biomass-derived hexamethylenediamine (HMD), enhancing the production of sustainable polyamide 66 (Leona™). This collaboration allows Asahi Kasei to evaluate bio-HMD as a feedstock, aiming to be first-to-market in sustainable engineering plastics for automotive and electronics. Asahi Kasei targets carbon neutrality by 2050, with bio-HMD potentially reducing greenhouse gas emissions. The partnership aligns with increasing global demand for eco-friendly materials in manufacturing.
Asahi Kasei Medical plans to expand its production capacity for Planova™ filters by constructing a new assembly plant in Nobeoka, Miyazaki, Japan. This facility aims to enhance manufacturing automation and efficiency, with construction set to begin in Q3 2022 and completion expected in early 2024. The demand for Planova™ filters has surged due to the COVID-19 pandemic's impact on the biotherapeutics market. Asahi Kasei Medical has been investing in production capacity to meet this demand, reinforcing its position as a market leader in virus filtration.